



Docket No. 97N-0217

Comments on "PROPOSALS TO INCREASE THE AVAILABILITY OF APPROVED ANIMAL DRUGS FOR MINOR SPECIES AND MINOR USES."

A. MODIFICATION OF EXTRALABEL PROVISIONS

0542 '98 JAN 20 19:52

- Will the proposed modification of extralabel provisions and suggested sunset period provide adequate and appropriate temporary relief until approved products are made available, or will it serve as a disincentive to the pursuit of approvals?

Modification of extralabel provisions of AMDUCA would make possible the use of antibiotics in fish feeds, and this is needed. In the catfish industry there are 3 FDA approved food additive antibiotics, but realistically there is only 1, Romet-30. Terramycin is usable only in sinking formulations of fish feed and there are few catfish producers using sinking feeds. Sulfamerazine is no longer on the market. There are some problems with Romet-30; it is unpalatable and expensive.

A sunset clause would only push back the day when the provisions of AMDUCA take effect. Unless some plan is adopted to hasten and simplify drug approval for aquaculture usage, in 10 years there will likely be only 1 or 2 more approved feed additives whether the extralabel provisions of AMDUCA are modified or not.

Would it be possible for FDA to modify its INAD policy so as to allow fish producers who need to use extralabel medicated feeds to do so in conjunction with an INAD coordinator who could use the treatment episode to establish efficacy?

- Should the proposed modifications be extended to include reproductive hormones and implants?

It is not clear how the proposed modifications relate to reproductive hormones and implants. Reproductive hormones might be in a feed additive form, but implants?

B. REMOVAL OF DISINCENTIVES

- Will the suggested strategies be sufficient to remove the existing regulatory disincentives?

1. Lack of enforcement resources. This is not thought to be a serious disincentive. True there are few therapeutic drugs approved for fish, however there are no unapproved drugs in competition with any drug that is now under consideration for FDA approval.

2. Changes in the Standard for Regulatory Action. If this change were made it should simplify enforcement and reduce the potential manpower and funding now committed to enforcement.

97N-0217

E
C 56



Comments on "PROPOSALS TO INCREASE THE AVAILABILITY OF APPROVED ANIMAL DRUGS FOR MINOR SPECIES AND MINOR USES."

3. Assurance that an Existing Approval Would Not Be at Risk. It is questionable whether this is a serious disincentive. Does FDA have the authority to "open up" a prior approval for review? If data from the parent application is insufficient to support claims made for a minor use drug, it simply does not support the minor use claim and it should not jeopardize the parent application in anyway. If data do support a minor use claim, that says nothing about the quality of the parent application which was for a different purpose submitted under different (?) requirements. Grandfathering is still recognized.

In general, the main disincentive was not addressed--it is not profitable to try to market minor use drugs. The single proposal that was made that would address this was a significant tax incentive.

C. ENHANCEMENT OF EXISTING PROGRAMS FOR DATA DEVELOPMENT

- Are there additional existing congressional research funds which could be expanded for minor use research?

These are good proposals and would directly affect the amount of drug research undertaken. Cooperative Research and Development Agreements (CRADA's) should also be encouraged in USDA, Interior, and Commerce. CRADA's are commonly developed between FDA laboratories and private groups and in ARS laboratories in areas other than minor use drugs. Pharmaceutical companies and producers of other aquaculture chemicals may not be aware of the existence of CRADA's.

- Would the proposed database be useful to parties interested in furthering the approval of minor use products? If so, how might it be developed most cost effectively?

What real purpose would be served by this database? To acquaint those with a curiosity to minor diseases and drugs. Any person with a professional interest in a minor disease or drug will have the information they need. So-called scientific databases often contain only superficial information.

E. DATA SHARING BY MAJOR SPECIES NADA HOLDERS

- Is it fair to require the sharing of data?

No! And fair is not the issue. It is intrusive. Let the minor use sponsor negotiate with the pioneer sponsor to purchase or otherwise agree upon use of the data, but don't attempt to create law saying FDA can horn in on any data it choses.



Comments on "PROPOSALS TO INCREASE THE AVAILABILITY OF APPROVED ANIMAL DRUGS FOR MINOR SPECIES AND MINOR USES."

F. CREATION BY STATUTE OF A "MINOR USE ANIMAL DRUG" PROGRAM

- Would a statutory designation of "minor use animal drug" similar to the statutory designation of "human orphan drug" be useful?

Yes.

- Are the incentives associated with this strategy a necessary component of the overall proposed "Minor Use Animal Drug Program"?

Yes.

I. INTERNATIONAL HARMONIZATION

- Could non-governmental input facilitate equivalency determinations?

That would appear to be the most efficient way in combination with agency activity.

- Are there sufficient numbers of foreign approvals to justify establishing this program?

Absolutely!

Bill Griffin

FedEx USA Airbill

FedEx
Tracking
Number

800197143286

0200

Form
I.D. No.

SNA21

Recipient's Copy

1 From 

Date 1-16-95
Sender's Name Elly K. Cullen Phone (870) 673-4483

Company SNARC USDA ARSAddress 2955 HWY 130 EASTCity STUTTGART State AR ZIP 72160

Dept./Floor/Suite/Room


2 Your Internal Billing Reference Information

3 To
Recipient's Name _____ Phone () _____

Company 1001 Locks Management Co.
Address 124120 Parklawn, L. N.
(To "HOLD" at FedEx location, print FedEx address here) Dept./Floor/Suite/Room _____
☐ Check here if residence (Extra charge applies for FedEx Express Saver)

City 1001 Hg State AR ZIP 72557**For HOLD at FedEx Location check here**☐ **Hold Weekday**
(Not available with
FedEx First Overnight)☐ **Hold Saturday**
(Available for FedEx Priority Overnight
and FedEx 2Day only)

(Not available at all locations)

For Saturday Delivery check here☐ (Extra Charge. Not available to all locations)
(Available for FedEx Priority Overnight
and FedEx 2Day only)

8 0 0 1 9 7 1 4 3 2 8 6

4a Express Package Service Packages under 150 lbs.Delivery commitment may
be later in some areas.☒ **FedEx Priority Overnight**
(Next business morning)☐ **FedEx Standard Overnight**
(Next business afternoon)☐ **FedEx 2Day***
(Second business day)☐ **FedEx Express Saver***
(Third business day)☐ **FedEx First Overnight**
(Earliest next business morning delivery to select locations)
(Higher rates apply)* FedEx Letter Rate not available.
Minimum charge: One pound rate.**4b Express Freight Service Packages over 150 lbs.**Delivery commitment may
be later in some areas.☐ **FedEx Overnight Freight**
(Next business day)☐ **FedEx 2Day Freight**
(Second business day)☐ **FedEx Express Saver Freight**
(Up to 3 business days)

(Call for delivery schedule. See back for detailed descriptions of freight services.)

5 Packaging☒ **FedEx
Envelope**☐ **FedEx
Pak**☐ **FedEx
Box**☐ **FedEx
Tube**☐ **Other
Pkg.****6 Special Handling**

Does this shipment contain dangerous goods?

☐ Yes (As per attached
Shipper's
Declaration)☐ Yes (Shipper's
Declaration
not required)☐ Dry IceDry Ice, 9, UN 1845 III _____ kg, 904
(Dangerous Goods Shipper's Declaration not required)CA ☐ Cargo Aircraft Only**7 Payment**Bill to: ☒ **Sender**
(Account no. in
section 1 will be billed)☐ **Recipient**☐ **Third Party**☐ **Obtain Recipient
FedEx Account No.**☐ **Credit Card**☐ **Cash/
Check**

Total Packages

Total Weight

Total Declared Value*

Total Charges

\$.00

* When declaring a value higher than \$100 per shipment, you pay an additional charge. See SERVICE
CONDITIONS, DECLARED VALUE, AND LIMIT OF LIABILITY section for further information.

Credit Card Auth.

8 Release Signature

Your signature authorizes Federal Express to deliver this shipment without obtaining a signature and agrees to indemnify and hold harmless Federal Express from any resulting claims.

Questions?

Call 1-800-Go-FedEx (800)463-3339

287

WCSL 0697
Rev. Date 5/97
Form #150354
©1994-97 FedEx
PRINTED IN U.S.A.

002760485 2